- Home
- TSBK vs RIGL Comparison
TSBK vs RIGL Comparison
Compare TSBK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSBK
- RIGL
- Stock Information
- Founded
- TSBK 1915
- RIGL 1996
- Country
- TSBK United States
- RIGL United States
- Employees
- TSBK N/A
- RIGL N/A
- Industry
- TSBK Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- TSBK Finance
- RIGL Health Care
- Exchange
- TSBK Nasdaq
- RIGL Nasdaq
- Market Cap
- TSBK 244.2M
- RIGL 291.9M
- IPO Year
- TSBK 1998
- RIGL 2000
- Fundamental
- Price
- TSBK $28.24
- RIGL $16.05
- Analyst Decision
- TSBK
- RIGL Buy
- Analyst Count
- TSBK 0
- RIGL 4
- Target Price
- TSBK N/A
- RIGL $31.13
- AVG Volume (30 Days)
- TSBK 14.0K
- RIGL 212.0K
- Earning Date
- TSBK 10-28-2024
- RIGL 11-05-2024
- Dividend Yield
- TSBK 3.36%
- RIGL N/A
- EPS Growth
- TSBK N/A
- RIGL N/A
- EPS
- TSBK 3.03
- RIGL N/A
- Revenue
- TSBK $74,387,000.00
- RIGL $130,201,000.00
- Revenue This Year
- TSBK N/A
- RIGL $38.26
- Revenue Next Year
- TSBK N/A
- RIGL $24.21
- P/E Ratio
- TSBK $9.52
- RIGL N/A
- Revenue Growth
- TSBK N/A
- RIGL 7.48
- 52 Week Low
- TSBK $23.93
- RIGL $7.10
- 52 Week High
- TSBK $32.24
- RIGL $17.30
- Technical
- Relative Strength Index (RSI)
- TSBK 36.35
- RIGL 66.76
- Support Level
- TSBK $29.83
- RIGL $15.51
- Resistance Level
- TSBK $30.59
- RIGL $17.18
- Average True Range (ATR)
- TSBK 0.64
- RIGL 0.88
- MACD
- TSBK -0.28
- RIGL 0.12
- Stochastic Oscillator
- TSBK 0.00
- RIGL 70.34
About TSBK Timberland Bancorp Inc.
Timberland Bancorp Inc is a bank holding company. The bank offers a variety of services such as checking accounts, online and mobile banking, savings accounts, home loans, consumer loans, construction loans, business rewards, cash management, small business solutions, and business checking accounts among others. Company also offers loans to real estate, including residential and commercial / multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans and land loans. The company mainly operates in the United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.